Cases
Cases
Updated Oct 20, 2:03 AM ET
BioXcel is seeking approval to sell substantially all assets to Teva and then liquidate its remaining estates; Teva was selected after no competing qualified bid emerged, according to the October 19 sale declaration Dkt. 251. The next material step is the October 21, 2026 hearing on the contested sale and proposed plan solicitation procedures, as set out in the amended hearing agenda Dkt. 257.
Omnibus10:00 AM ETDkt. 75Certification of Counsel Regarding Scheduling of Omnibus Hearing Dates Filed by BioXcel Therapeutics, Inc.. (Kochenash, Jared)
in 27 daysSearch available documents for this case. Full docket access requires Pro.
Open case researchBioXcel Files Chapter 11 With Teva Bid of $57.5M Plus Milestones ·
Case facts and filing dates come from court records.
Updated Oct 20, 2:03 AM ET
BioXcel is seeking approval to sell substantially all assets to Teva and then liquidate its remaining estates; Teva was selected after no competing qualified bid emerged, according to the October 19 sale declaration Dkt. 251. The next material step is the October 21, 2026 hearing on the contested sale and proposed plan solicitation procedures, as set out in the amended hearing agenda Dkt. 257.
Omnibus10:00 AM ETDkt. 75Certification of Counsel Regarding Scheduling of Omnibus Hearing Dates Filed by BioXcel Therapeutics, Inc.. (Kochenash, Jared)
in 27 daysSearch available documents for this case. Full docket access requires Pro.
Open case researchBioXcel Files Chapter 11 With Teva Bid of $57.5M Plus Milestones ·
Case facts and filing dates come from court records.